Results For "0"

A Bird’s Eye View on Rare Diseases: Key Drug Development Considerations for Thyroid Eye Disease Blog Post

New therapeutics discovery and development for ocular diseases have been traditionally associated with a low probability of technical and regulatory success. The significant unmet medical needs for ocular diseases include…

Certara Announces Release of Pinnacle 21 Enterprise Software Blog Post

New metrics and analytics capabilities enable informed decision making for biopharmaceutical clients PRINCETON, N.J., Dec. 13, 2021 — Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ（Nasdaq：CERT) はCERT), a global leader in biosimulation, today announced the…

Accelerating the establishment of precision medicine using PK-PD/TD modeling Blog Post

サターラの日本チームが京都薬科大学 薬物動態学分野　助教である河渕真治先生に初めてお会いしたのは、河渕先生が同大学の博士課程に在籍されている時でした。当時、当社のソフトウェア・トレーニングコースに頻繁に参加されており、His proactive…

Dose Optimization Using Population PK for an Orphan Drug Blog Post

ノーベルファーマ社のラパリムス®錠（シロリムス）は、米国ファイザー社が臓器移植の免疫抑制剤として販売している経口薬から開発されたノーベルファーマ社のオーファンドラッグです。mTOR阻害剤という特性から、アカデミアの...

Industry Metrics for CDISC Controlled Terminology Blog Post

Sergiy Sirichenko summarizes industry metrics across many studies and sponsors to produce an overall picture of CDISC Controlled Terminology utilization.

Certara Launches Fellowship Program in Africa for Applied Pharmacometrics Training Blog Post

PRINCETON, N.J.— 2021年11月8日 — Certara, Inc, a global leader in biosimulation, today announced that it is launching a fellowship program for doctoral-level scientists from Africa, in partnership with…

Certara’s Partner Network Page

Certara’s Partner Network Certara and our partners are constantly evolving, broadening our expertise and our footprint in order to meet the diverse and emerging needs of our customers around the...

Developing Targeted Covalent Inhibitor Drugs: 3 Key Considerations Blog Post

従来の薬物作用機構は、リガンドと生物学的標的との可逆的で非共有結合的な相互作用に依存していました。一方、標的化共有結合阻害剤（TCI）は...

Defining path-to-market strategy through a data-driven and scientific approach Blog Post

How Certara supported a gene therapy manufacturer by using a selection of gateway and value indications as the foundation for the next phase of clinical development.

Rare and Neglected Diseases Resource Center Page

Rare and Neglected Diseases Resource Center Developing drugs for rare diseases poses a range of clinical, regulatory, and commercial challenges. 患者数が少なく、希少疾患の研究が限られているため、臨床エンドポイント、バイオマーカー、アウトカム指標の設定が困難です。...